Advertisement

Issue 7, Volume 127

Cover Figure: Novel regulatory mechanism of ICAM-1 function on neutrophils.See the article by Woodfin et al.

WASHINGTON, February 18, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
In a large detailed retrospective registry analysis, Kanate and colleagues show for the first time that the outcome of haploidentical stem cell transplantation in the context of reduced-intensity conditioning is similar to that of matched unrelated donor (URD) transplantation in patients with malignant lymphoma. These data will likely change the landscape for the use of haploidentical vs URD transplants in lymphoma.

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas
In this week's Blood, Culjkovic-Kraljacic et al demonstrate that targeted inhibition of the mRNA translation initiation factor eIF4E is an effective strategy to reduce expression of the MYC, BCL2, and BCL6 oncoproteins in aggressive B-cell lymphomas.

When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data
The increased burden of venous thromboembolism (VTE) among breast cancer patients is well-established. In this issue of Blood, Walker et al estimate VTE rates associated with current breast cancer treatments in time windows before, during, and after treatment. The study of over 13,000 women provides data on the changing rates of VTE over the time course of treatment with chemotherapy, hormonal therapy, surgery, and clinical observation.

Apelin: an antithrombotic factor that inhibits platelet function
In the current issue of Blood, Adam and colleagues report a previously unidentified mechanism by which platelet activation may be controlled during hemostasis and thrombosis. The authors show that apelin, a plasma peptide known for its ability to modulate blood pressure and angiogenesis, is a potent inhibitor of platelet function as well.

ICAM-1-expressing neutrophils exhibit enhanced effector functions in murine models of endotoxemia
The study in this week's Blood by Woodfin et al. reveals a novel regulatory mechanism that controls the expression and function of ICAM-1 on neutrophils. Thus, the investigators identify an additional regulator of neutrophil effector responses in host defense.

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
Internal tandem duplications of the Fms-like tyrosine kinase 3 receptor (FLT3-ITD) are found in 30% of acute myeloid leukemia (AML) cases and are associated with an unfavorable prognosis. In their study in this week's Blood, Larrue and colleagues show that leukemias bearing FLT3-ITD mutations are exquisitely sensitive to proteasome inhibitors. They provide novel insight into an apoptotic pathway that involves autophagy-dependent FLT3-ITD degradation. These findings may have profound implications for therapy.

Misshapen/NIK-related kinase (MINK1) is involved in platelet function, hemostasis, and thrombus formation
Yue and coworkers developed MINK1 knockout mice and, in this week's Blood, report experiments on the function of misshapen/NIK-related kinase 1 (MINK1), a signaling protein kinase, not previously investigated in platelets. They demonstrate an important role for this signaling molecule in platelet granule secretion and platelet activation as well as in vivo hemostasis and thrombosis.

Sickle cell disease: challenges and progress
In a series of reviews in this week's Blood, leading researchers provide five state-of-the-art updates on important biological, clinical, and therapeutic aspects of sickle cell disease.

The articles in this review series, Sickle cell disease: challenges and progress, include the following:

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.